
30
(The "Company" or "AEP")
Trading Statement and Delay in 2024 Audited Financial Statements
Delay to publication of the audited financial results for the year ended
As a result, the Company expects that its shares will be temporarily suspended from listing and trading from
AEP recognises the importance of timely financial reporting and remains committed to restoring its usual reporting timetable going forward.
Operating Performance from continuing operations
Notwithstanding the above, the Board presents the following underlying performance of the Company from continuing operations for the year ended
Our revenue is expected to be around
In 2024, our FFB and CPO production declined by 7% and 12%, respectively, compared to the previous year. The decline in production was partly due to our ongoing replanting programme and further influenced by broader regional conditions, particularly in the first half of the year, where excessive rainfall and flooding disrupted operations in certain regions.
|
Unit |
2024 (unaudited) |
2023 |
FFB production |
(' |
1,019.9 |
1,102.2 |
Mature plantation |
('000 ha) |
57.2 |
56.7 |
External FFB purchased |
(' |
988.9 |
1,080.2 |
CPO production |
(' |
396.7 |
449.0 |
Dividend
Accordingly, and in line with the Group's stated dividend policy, the Board is proposing to declare a final dividend of
The following dates are subject to confirmation, owing to the delay in the publication of the annual report and accounts. The dividend is scheduled to be paid on
Event |
Date |
Ex-Dividend Date |
|
Record Date |
|
For further enquiry, contact:
Marcus Chan Jau Chwen, Executive Director (Corporate Affairs)
Panmure Liberum +44 (0) 20 3100 2000
Amrit Mahbubani / Freddie Wooding
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the